Introduction
Low-dose dobutamine infusion remains in use as a therapeutic modality for patients with advanced congestive heart failure (CHF). Infusion of dobutamine and other inotropic agents has been associated with adverse cardiac outcomes, 1 -2 which may be partially mediated by ischemia. We have previously shown that stress-induced wall motion abnormalities (SWMA) with low-dose dobutamine occur in the presence of severe and extensive coronary disease suggesting that low-dose SWMA is due to ischemia. 3 We have also shown that low-dose SWMA most frequently occurs in segments with resting wall motion abnormalities. These segments may represent repetitively stunned or hibernating myocardium. Hibernating myocardium is vulnerable to further ischemic insult that can result in permanent injury. 4, 5 Patients with advanced left ventricular (LV) dysfunction with stunned or hibernating myocardium that are not revascularized are at high risk for cardiac death. 6, 7 The known poor outcome of medically treated patients with stunned or hibernating myocardium and the association of low-dose SWMA with ischemia and severe coronary artery disease (CAD) suggest that low-dose SWMA may be an indicator of patients at high risk for cardiac death.
In this study, we investigated the prognostic value of lowdose SWMA in medically treated patients with ischemic LV dysfunction. The survival of patients with low-dose SWMA was compared with the survival of patients with high-dose SWMA who are known to be a high risk group.
Methods

Patient Population
The study was approved by the Institutional Review Board of Indiana University. Patients with known CAD and chronic LV systolic dysfunction (wall motion abnormalities [WMA] involving ≥4 segments and reduced ejection fraction or reduced fractional shortening) referred for dobutamine echocardiography (DE) were eligible for the study. The study group was comprised of 235 medically treated patients who underwent low and peak-dose DE for assessment of myocardial viability at Indiana University hospitals over a 10 year period. Excluded were 366 patients with CAD and LV dysfunction who underwent DE for other indications during this time period. A total of 130 patients who had revascularization after DE were also excluded to avoid the confounding effects of revascularization on determining the prognostic impact of stress-induced ischemia.
Dobutamine Echocardiography
Dobutamine was administered in incremental fashion beginning at a dose of 5 µg/kg/min. The dose was increased to 10 µg/kg/min after 3 minutes and then by 10 µg/kg/min increments every 2 to 3 minutes to a peak-dose of 50 µg/kg/min. Intravenous atropine was used as needed to attain target heart rates of ≥85% of the patient's agepredicted maximal rate. Other endpoints for dobutamine infusion were the same as described in a previous study. 8 Echocardiograms in the parasternal long and short axis and apical 4-chamber and 2-chamber views were digitally stored at rest, at the end of the 5 and 10 µg/kg/min (low-dose) stages, and at peak-dose.
Echocardiography Analysis
Regional wall motion was assessed by an investigator blinded to the clinical stress testing and outcome data. Wall thickening and motion were analyzed and graded in 16 segments of the LV using a previously described system. 8 Rest, low (10 µg/kg/min), and peak-dose wall motion scores (WMS) were obtained by dividing the sum of individual segment scores by the number of segments scored. A blinded observer measured ejection fraction at rest using Simpson's method.
Low-dose SWMA was defined as a new WMA or worsening of a rest WMA at 5 or 10 µg/kg/min (except for akinesis at rest to dyskinesis). Segments with resting wall motion abnormalities that improved at 5 µg/kg/min and worsened at 10 µg/kg/min were considered to have lowdose SWMA and a biphasic response. Peak-dose SWMA was defined as a new WMA or worsening of a WMA at peak-dose (compared with wall motion at rest or at low-dose).
Study Groups
The patients were divided into 3 groups in an effort to determine the prognostic impact of low-dose SWMA. Because many patients had both low-dose SWMA and peakdose SWMA, patients with SWMA were divided into 2 groups based on the extent of low-dose SWMA and the extent of peak-dose SWMA.
Group 1 was comprised of patients with no ischemia on DE. Group 2 was comprised of patients with low-dose SWMA. This group included patients with ischemia only at low-dose and patients who had more ischemic segments at low-vs peak-dose. Group 3 was comprised of patients with SWMA occurring only at peak-dose and those who had the same number or more ischemic segments at peak-dose than at low-dose. Since group 2 (low-dose SWMA) and group 3 (high-dose SWMA) had some patients with both low and peak SWMA, a second survival analysis was conducted to compare the outcome of patients with low-dose SWMA alone with that of other patients with SWMA. For this analysis patients with SWMA were divided into 3 groups. The first group was comprised of patients with SWMA only at low-dose. The second group was comprised of patients with SWMA at low-and peak-dose. The third group was comprised of patients with SWMA only at peak-dose.
Follow-up
Follow-up was primarily retrospective and performed by telephone interview and review of medical records. The endpoint was cardiac death defined as death due to intractable heart failure, myocardial infarction, or sudden death.
Statistical Analysis
Continuous variables are reported as mean ± standard deviation (SD). A p value of <0.05 was considered to be statistically significant. One-way analysis of variance and χ 2 were used to compare clinical and echocardiographic variables between the study groups. Predictors of cardiac death were determined using Cox regression. Multivariate analysis was conducted incorporating variables that had P values <.05 on univariate analysis. KaplanMeier survival analysis was used to compare survival in the 3 patients groups. Statistical analysis was performed with SPSS version 14.0 for Windows (SPSS, Inc., Chicago, IL).
Results
Clinical Characteristics
The clinical and echocardiographic characteristics of the patient population are shown in Table 1 . The mean age was 62 ± 11 years, 39% had advanced heart failure (New York Heart Association [NYHA] class III or IV). The mean ejection fraction was 31% ± 8%.
Echocardiography
In group 1 (no ischemia), there were 85 patients. In group 2 (low-dose SWMA), there were 33 patients. Of these 33 patients, 62 of the 93 segments (67%) that exhibited low-dose SWMA had abnormal wall motion at rest. There were 19 patients in group 2 who had ischemia only at low-dose and 14 patients had more ischemic segments at low-vs peak-dose. In the 14 patients with more ischemic segments at low-vs peakdose, the mean number of segments with low and peak-dose SWMA were 3.6 and 2.0, respectively (p = 0.008).
In group 3, (peak-dose SWMA) there were 117 patients. A total of 60 patients had ischemia only at peak-dose. There were 57 patients in group 3 who had ischemia both at lowand peak-dose (with the same or more ischemic segments at peak-vs low-dose). In these 57 patients, the mean number Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; Hx, history; MI, myocardial infarction; NYHA, New York Heart Association; WMS, wall motion score.
of segments with peak-dose SWMA and low-dose SWMA were 3.2 and 1.8, respectively (p < 0.001).
The clinical and echocardiographic characteristics of the 3 groups are compared in Table 2 . The only difference in the study groups was that prior myocardial infarction was more common in patients with peak-dose SWMA.
Follow-up and Predictors of Cardiac Death
The mean follow-up was 4.1 ± 3.3 years. There were 123 cardiac deaths (52% of all patients). Table 3 shows univariate clinical predictors of cardiac death which were increasing age, diabetes, prior bypass grafting, advanced heart failure (NYHA class III or VI), use of lasix, use of digoxin, and use of angiotensin-converting enzyme inhibitors (ACEI). β-Blocker use was predictive of survival. Table 4 shows univariate stress echo predictors of cardiac death. Rest-, low-, and peak-dose WMS, the number of ischemic segments at low-dose, and the stress test group (low-dose SWMA or peak-dose SWMA vs negative stress test for ischemia) were predictors for cardiac death. Table 5 shows multivariate predictors of cardiac death. Low-dose SWMA and peak-dose SWMA were independent predictors of cardiac death. Age, diabetes, CHF NYHA class III or IV, and peak-dose WMS were also independent predictors. β-Blocker use independently predicted survival. Figure 1 shows the Kaplan-Meier survival analysis for the 3 groups. Low-dose SWMA and peak-dose SWMA groups had significantly poorer survival than the negative DE group (group 1 vs group 2, p = 0.001; group 1 vs group 3 p < 0.0001). Survival was the same in low-and peak-dose SWMA groups (p = 0.89). Figure 2 shows the results of the second survival analysis comparing 3 groups of patients with ischemia. Survival was compared in patients with low-dose SWMA alone to those with peak-dose SWMA alone, and with those who had both low-and peak-dose SWMA. Survival was not significantly different in these groups (low-dose SWMA alone vs peakdose SWMA alone, p = 0.594; low-dose SWMA alone vs lowand peak-dose SWMA, p = 0.238; and peak-dose SWMA alone vs low-and peak-dose SWMA, p = 0.455).
Survival Curves
Discussion
This study demonstrated that low-dose SWMA is an independent predictor of cardiac death in patients with ischemic LV dysfunction who are treated medically. The presence of low-dose SWMA identified patients with an equivalent risk of cardiac death to those with peak-dose SWMA. The majority of segments with low-dose SWMA had baseline dysfunction suggesting that this response to dobutamine is most common in segments with hibernation or stunning.
Low-Dose SWMA and Cardiac Death
We have previously shown that low-dose SWMA indicates the presence of severe and extensive CAD, and reduced collateral supply. 3 In our prior study, patients with low-dose SWMA had nearly a 100% frequency of multivessel disease indicating that low-dose SWMA is a marker for patients with high risk coronary anatomy. The finding that lowdose SWMA is also an indicator of a poor prognosis is not unexpected given the relationship of low-dose SWMA to severe and extensive CAD.
In this study, low-dose SWMA occurred predominantly in segments that had resting dysfunction. The resting dysfunction in these segments was likely a manifestation of repetitive stunning or hibernation. Studies utilizing positron emission tomography have shown that patients with hibernating or stunned myocardium characterized by Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CHF, congestive heart failure; Hx, history; MI, myocardial infarction; NYHA, New York Heart Association; WMS, wall motion score.
enhanced glucose uptake relative to perfusion (perfusionmetabolism mismatch) are at increased risk for cardiac events if revascularization is delayed or not performed at all. 6, 7 Regions with perfusion-metabolism mismatch may represent myocardium that is especially vulnerable to ischemia because of severe disease causing reduction in resting myocardial perfusion or severe limitation in perfusion reserve. Minor increases in oxygen demand or reductions in perfusion may lead to ischemic injury and progressive cell death.
4,5
The predominance of low-dose SWMA in stunned or hibernating regions may be confirmatory evidence that these regions are vulnerable to ischemia that could be produced by minor levels of physical exertion or minor alterations in myocardial perfusion. Localized injury caused by either demand ischemia or reduction in myocardial oxygen supply will hasten deterioration of global LV function and may lead to death from intractable heart failure. Hibernating myocardium has also been shown to be a substrate for generation of lethal ventricular arrhythmias. 9 Ischemia, occurring in regions with hibernation, could serve as a trigger for malignant ventricular arrhythmias.
Clinical Implications
Low-dose dobutamine infusion remains in widespread use for short-term treatment of hospitalized patients with advanced heart failure. Intermittent or prolonged infusion of low-dose dobutamine also remains in use for outpatients who are potential transplant candidates or those who cannot obtain symptom relief through other therapies.
One of the clinical implications of this study is that echocardiographic imaging performed at the onset of therapeutic infusions of low-dose dobutamine may provide both useful diagnostic and prognostic information. Our data suggests that echocardiographic monitoring of patients with ischemic LV dysfunction may have a high yield for obtaining clinically relevant information. In our study, over a third of patients had low-dose SWMA indicating that ischemia with low-dose dobutamine infusion is common in Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CHF, congestive heart failure; CI, confidence interval; HR, hazard ratio; Hx, history; MI, myocardial infarction; NYHA, New York Heart Association.
patients with severe and extensive CAD and left ventricular dysfunction. In a previous investigation, evaluating a similar population of patients, we found that the multivessel disease was the strongest independent predictor of lowdose ischemia. 3 Afridi et al. and Cornel et al. have reported a lower incidence of ischemia with low-dose dobutamine. 10 -11 Unlike our study, these investigations did not assess for ischemia in segments with normal wall motion at rest. Additionally, Afridi et al. investigated a population with relatively limited disease where only 10% of patients had 3-vessel CAD. The detection of low-dose ischemia identifies those at risk for cardiac death if they are managed with medical therapy. Our findings suggest that some consideration might be given to revascularization of those patients who demonstrate low-dose SWMA. We did not have a revascularized cohort of patients with low-dose SWMA to determine the relative value of revascularization vs medical therapy in patients with low-dose SWMA. However, revascularization is known to improve survival in patients with evidence of hibernation suggesting that patients with the echocardiographic correlate of perfusion-metabolism mismatch might also benefit from revascularization. 6, 7 Additionally, patients with CAD and LV dysfunction who have ischemia with high doses of dobutamine are known to have a survival benefit from revascularization. 12, 13 The finding of low-dose ischemia during therapeutic dobutamine infusion may prompt consideration of reduction of the dose of dobutamine to a lower level that does not result in worsening of wall motion. This may be particularly important in patients in whom prolonged inotropic infusion is needed. Schulz et al. demonstrated that extended infusion of dobutamine may precipitate ischemic injury in hibernating myocardium.
14 The long-term use of inotropic infusions has been associated with poorer outcomes in those with advanced CHF. 1, 2 Our data suggests that ischemia may be a link between inotropic therapy and their apparent adverse effects on outcome in patients with ischemic LV dysfunction.
The finding of low-dose ischemia during a dobutamine stress study may enable early termination of testing in selected patients who may be considered at increased risk of ischemic complications or arrhythmias with higher doses of dobutamine. However, the finding of low-dose ischemia may not obviate the need for higher dose infusion of dobutamine. Demonstration of ischemia in other coronary territories and assessment of the extent of ischemia may provide additional Abbreviations: CHF, congestive heart failure; CI, confidence interval; HR, hazard ratio; NYHA, New York Heart Association; SWMA, stress-induced wall motion abnormalities; WMS, wall motion score.
diagnostic and prognostic information beyond that obtained with the finding of low-dose ischemia.
Limitations
Distinguishing the relative prognostic impact of low-dose SWMA compared with high-dose SWMA was challenging because many patients had both findings. However, survival analysis of patients with low-dose SWMA alone showed that these patients had similarly poor outcome to those who had high-dose SWMA alone (Figure 2 ). Peak-dose SWMA (grp 3) Figure 1 . Survival of all patients (group 1 = no ischemia; group 2 = low-dose SWMA; group 3 = peak-dose SWMA). Patients with no ischemia had significantly better survival than patients with low-dose SWMA or peak-dose SWMA. Survival was equally poor in the groups with low-and peak-dose SWMA. Abbreviations: DE, dobutamine echocardiography; SWMA, stress-induced wall motion abnormalities.
Patients were enrolled over an extended period of time during which significant changes in medical therapy occurred. The frequency of ACEI and β-blockers usage is lower than would be expected. However, the frequency of ACEI and β-blocker use in our study was comparable to that in other studies enrolling patients in the 1990s. 15 . Survival in patients with SWMA (group 1 = low-dose SWMA only; group 2 = low-and peak-dose SWMA; group 3 = peak-dose SWMA only). Survival was not significantly different among the 3 groups of patients with SWMA. Abbreviation: SWMA, stress-induced wall motion abnormalities.
